

Retatrutide + Cagrilintide Dosing Chart

An investigational pairing of the triple agonist retatrutide with the amylin analog cagrilintide. No combined product is approved. Commonly discussed doses: 2.4 mg–2.4 mg. No established dosing exists for this combination — it is an investigational concept, not an approved or standardized product. Figures shown reflect the cagrilintide component's published dosing. Any actual product is compounded and unstandardized.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved. Neither retatrutide nor cagrilintide is approved, and no combined product exists as an approved drug.

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.4 mg
1 mL	10	24 u
2 mL	5	48 u
3 mL	3.33	72 u

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/retatrutide-plus-cagrilintide

Retatrutide + Cagrilintide dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.